Evolving Oncology Treatment Options— Recent Approvals and a Look to the Future

ACPE UAN #:  0233-0000-20-04-HO1-P

Release Date:  November 9, 2020

Expiration Date:   November 9, 2023

Activity Type:    Knowledge-based

Contact Hours:   1

Activity Fee:  Member:  Free        Non-Member:  Free

Target Audience: Pharmacists who practice in managed care settings.

Activity Description

Over 1,100 biopharmaceutical products are currently in the oncology pipeline andnumerous new treatments approved by the FDA each year. Additionally, biosimilar treatment options are now available for many oncologic treatments, potentially offering more cost-effective options. With the abundance of emerging oncologic treatment options, providers and managed care organizations are challenged to determine where these new treatments fit within current treatment regimens and appropriate placement within formularies. These assessments may be even more complex due to the use of novel regulatory requirements for drug approvals and approvals based on trials with small numbers of patients. Comparative efficacy data of various approaches are lacking, and heterogeneity among patient populations complicate comparisons across clinical trials.  The emergence of multiple treatment options using different mechanisms of action has complicated determination of the best approaches to treatment sequencing.  

This home study activity will review recently-approved oncologic therapies and highlight selected treatments in late-stage clinical trials. Examples of recently-approved treatments for multiple myeloma, breast cancer, lung cancer, and emerging classes of oncologic treatments will be discussed.

Learning Objectives:

At the completion of this activity, participants should be able to:

  1. Describe newly-approved chemotherapeutic, immuno-oncologic, biologic, and biosimilar
    treatment options for oncology.
  2. Discuss novel regulatory pathways for approving oncologic treatments.
  3. Describe strategies for determining how to implement newly-approved therapies within
    current oncologic treatment paradigms for multiple myeloma, breast cancer, and lung

Schedule of Educational Activity:

This activity consists of an audio recording, pre-test assessment questions (not required to pass to continue), post-test questions (required to pass with a score of 70% or higher), and a specific activity evaluation.

Accreditation Statement:

The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities.  AMCP intends that all CPE activities be independent, objective, balanced, evidence-based, and free of any commercial bias.

CPE Requirements:   

Participants should claim CPE credit for this home study activity only if they have not claimed credit for the live activity presented at Specialty Connect 2020 Virtual.

CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor.  Please allow 72 hours for processing and posting in your National Association of Boards of Pharmacy (NABP) e-Profile account.

To receive credit for a home study activity you must:

  • Review the full content of the home study activity.
  • Complete the post-test and achieve a score of 70% or higher.
  • Complete a specific activity evaluation.

Statement of Commercial Support:

This program is supported by independent medical education grants from Celgene Corporation and Pfizer Inc.

System Technical Requirements/Viewing Requirements

Courses and continuing education activities are delivered via your Web browser and Acrobat PDF.  For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for all continuing education activities. 

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-20-004-H01-P 1 Contact Hour November 09, 2020 - November 09, 2023